The Business ReportTargacept's Lead Compound Ties PlaceboNovember 11, 2011 | David FordTargacept, with over 140 employees is the Piedmont Triad Research Park’s flagship biotech company. CEO, Don deBethizy spun the drug-discovery company out of R.J. Reynolds Tobacco Co. 11 years ago, and it’s been growing steadily ever since.
Targacept has an enormous pipeline of new drugs at various stages of completion that deal with brain disorders from Alzheimer’s to Parkinson’s. One of them is the company's lead compound, an antidepressant named TC-5214—its first to reach the final stage of clinical trials. On Tuesday, while still in that stage, 5214 met with a major set back.
Last week Business Journal Contributing Writer and Director of the Journalism Program at Wake Forest University Justin Catanoso spoke with deBethizy about the challenges and promise of bringing a new drug to market. Justin shared that conversation with WFDD’s David Ford. Full archive of The Business Report >>
|
|
|
| Su |
M |
T |
W |
Th |
F |
Sa | | | 1 | 2 | 3 | 4 | 5 | 6 | | 7 | 8 | 9 | 10 | 11 | 12 | 13 | | 14 | 15 | 16 | 17 | 18 | 19 | 20 | | 21 | 22 | 23 | 24 | 25 | 26 | 27 | | 28 | 29 | 30 | | | | |
|
